Teva Pharmaceutical falls 6% on eve of Q3 earnings show | Seeking Alpha
2017 closes with record approvals of generics, novel drugs; 2018 begins with reprieves for Teva | Radio Compass Blog
Teva Stock Dives As The Sales Downfall Continues For Its Biggest Product | Investor's Business Daily
Why Teva Pharmaceuticals Stock Has Two A-Products In The Bag (NYSE:TEVA) | Seeking Alpha
US Congress grills Teva CEO on Copaxone price hikes - Globes
Pharma giant Teva promises to create over 800 jobs in N.J. Are they worth $40M? - nj.com
15. Teva Pharmaceutical Industries | FiercePharma
Global Fluconazole Market 2018 - Pfizer, Bayer, Teva
Feds accuse Teva of $300M in kickbacks for MS drug - Drug Discovery and Development
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
Teva Announces New Brand Positioning and Visual Identity in North America
What's behind the timed resurgence of lawsuits against Teva? | Ctech
Teva Pharmaceutical Industries and opioid settlement: What to know
Why Teva Pharmaceuticals Stock Has Two A-Products In The Bag (NYSE:TEVA) | Seeking Alpha
Teva earnings Q2 2018 | AlphaStreet
Teva Wins Three, Loses Six in Patent Battle Over Migraine Drug | BioSpace
18. Teva Pharmaceutical Industries | FiercePharma
Teva concludes $703m women's health products deal with CVC Capital - Pharmaceutical Technology
Teva Pharmaceuticals: Israeli drugmaker to cut 14,000 jobs - BBC News
Patients Eagerly Awaited a Generic Drug. Then They Saw the Price. - The New York Times
Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets | News Direct
Teva Pharm to lay off a quarter of workforce, suspends dividend | Reuters
Teva Selling $3.5 Billion of Junk Bonds to Refinance Debt - Bloomberg
Teva chief reports 'strong progress' in restructuring plan | The Times of Israel